You are here: Industry Insights > Biopharma

News List

Teva & Genedata Enter Biopharma Partnership contractpharma
March 27, 2019
Teva will use Genedata's workflow platform to streamline the identification, engineering, and characterization of novel biopharmaceuticals drugs.
GT Biopharma Restructures Management Team contractpharma
March 27, 2019
Cataldo named chief executive officer, Weldon appointed as chief financial officer.
BioPlan Benchmarks the State of Biopharma Mfg. pharmafocusasia
March 14, 2019
BioPlan Associates recently launched its 16thAnnual Survey on Biopharmaceutical Manufacturing. One of the industry’s most comprehensive reports of its kind, BioPlan benchmarks current global and regional trends affecting the bio industry.
GlaxoSmithKline CEO Walmsley snags a pay bump but still earns less than male peers fiercepharma
March 14, 2019
GlaxoSmithKline chief Emma Walmsley saw her pay package swell in 2018 but still less than male peers.
Pharma stocks fell in 2018, but innovation soared with 62 new drugs set for $24B in yearly sales: report fiercepharma
March 01, 2019
Investors ended 2018 with a sour outlook for biopharma, as fourth-quarter economic worries erased massive share-price gains the sector had enjoyed in the first half of the year. Dealmaking was down during the year, as were licensing deals.
Servier terminates CTI cancer pact following clinical failure fiercebiotech
February 28, 2019
Servier has terminated its Pixuvri collaboration agreement with CTI BioPharma. The action comes seven months after the B-cell non-Hodgkin lymphoma drug failed a key clinical trial....
Notable Labs brings on 2 development executives ahead of its first blood cancer trials fiercebiotech
February 27, 2019
After launching its first in-house R&D program last month, cancer drug-testing startup Notable Labs has brought on two biopharma executives to take charge of its clinical operations and drug development work....
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report fiercepharma
February 22, 2019
This year is already shaping up to be a big one for biopharma mergers and acquisitions, with Bristol-Myers Squibb’s planned $74 billion buyout of Celgene well underway.
Turbulent times for Xencor as FDA slaps hold on AML bispecific fiercebiotech
February 22, 2019
Xencor didn’t have the best start to 2019—in January, its partner Novartis returned the rights to a bispecific antibody it had licensed as part of a 2016 deal worth up to $2.41 billion....
Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices fiercepharma
January 16, 2019
Biopharma experts predicting an M&A boom this year said one thing might thwart that surge of dealmaking: federal action on drug prices. If buyers can't charge what they want for the drugs they pick up in a merger, then the value of that deal could quickly

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page